Journal article · 2021 · Open access

A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India

Prasad Suryakant Kulkarni, Chandrasekaran Padmapriyadarsini, Johan Vekemans, Ashish Bavdekar, Madhu Gupta, Praveen Kulkarni, BS Garg, Nithya Gogtay, Muralidhar Tambe, Sanjay Lalwani, Kiranjit Singh, Renuka Munshi and 19 more

EClinicalMedicine, 42, 101218 · Published 30 November 2021 · DOI 10.1016/j.eclinm.2021.101218

Open PDFView at the publisherCite this paper

In brief

“A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India” is a 2021 journal article by Prasad Suryakant Kulkarni and 30 co-authors, published in EClinicalMedicine. OpenAlex counts 37 citations as of 20 November 2026, which puts it in the top 5% of works published in 2021 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at EClinicalMedicine.

Citations
37
Most cited in
2024 (14)
Field-weighted impact
2.45
References
17
Authors
31

Abstract

BACKGROUND: This phase 2/3 immunobridging study evaluated the safety and immunogenicity of the ChAdOx1 nCoV-19 Coronavirus Vaccine (Recombinant) (SII-ChAdOx1 nCoV-19), manufactured in India at the Serum Institute of India Pvt Ltd (SIIPL), following technology transfer from the AstraZeneca. METHODS: This participant-blind, observer-blind study randomised participants 3:1 to SII-ChAdOx1 nCoV-19 or AZD1222 (ChAdOx1 nCoV-19) (immunogenicity/reactogenicity cohort) and 3:1 to SII-ChAdOx1 nCoV-19 or placebo (safety cohort). The study participants were enrolled from 14 hospitals across India between August 25 and October 31, 2020. Two doses of study products were given 4 weeks apart. The primary objectives were to demonstrate non-inferiority of SII-ChAdOx1 nCoV-19 to AZD1222 in terms of geometric mean titre (GMT) ratio of anti-SARS-CoV-2 spike IgG antibodies 28 days after the second dose (defined as lower limit of 95% CI >0·67) and to determine the incidence of serious adverse events (SAEs) causally related to SII-ChAdOx1 nCoV-19. The anti-spike IgG response was assessed using a multiplexed electrochemiluminescence-based immunoassay. Safety follow-up continued until 6 months after first dose. Trial registration: CTRI/2020/08/027170. FINDINGS: 1601 participants were enrolled: 401 to the immunogenicity/reactogenicity cohort and 1200 to the safety cohort. After two doses, seroconversion rates for anti-spike IgG antibodies were more than 98·0% in both the groups. SII-ChAdOx1 nCoV-19 was non-inferior to AZD1222 (GMT ratio 0·98; 95% CI 0·78-1·23). SAEs were reported in ≤ 2·0% participants across the three groups; none were causally related. A total of 34 SARS-CoV-2 infections were reported; of which 6 occurred more than 2 weeks after the second dose; none were severe. INTERPRETATION: SII-ChAdOx1 nCoV-19 has a non-inferior immune response compared to AZD1222 and an acceptable safety/reactogenicity profile. Pharmacovigilance should be maintained to detect any safety signals. FUNDING: SIIPL funded the contract research organisation and laboratory costs, while the site costs were funded by the Indian Council of Medical Research. The study vaccines were supplied by SIIPL and AstraZeneca.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Kulkarni, P. S., Padmapriyadarsini, C., Vekemans, J., Bavdekar, A., Gupta, M., Kulkarni, P., Garg, B., Gogtay, N., Tambe, M., Lalwani, S., Singh, K., Munshi, R., Meshram, S., Selvavinayagam, T. S., Pandey, K., Bhimarasetty, D. M., Ramakrishnan, S. R., Bhamare, C., Dharmadhikari, A., . . . Gunale, B. (2021). A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India. EClinicalMedicine, 42, 101218. https://doi.org/10.1016/j.eclinm.2021.101218

MLA 9

Kulkarni, Prasad Suryakant, et al. “A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India.” EClinicalMedicine, vol. 42, 2021, p. 101218. https://doi.org/10.1016/j.eclinm.2021.101218.

Chicago

Kulkarni, Prasad Suryakant, Chandrasekaran Padmapriyadarsini, Johan Vekemans, Ashish Bavdekar, Madhu Gupta, Praveen Kulkarni, BS Garg, et al. 2021. “A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India.” EClinicalMedicine 42: 101218. https://doi.org/10.1016/j.eclinm.2021.101218.

Harvard

Kulkarni, P. S. et al. (2021) ‘A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India’, EClinicalMedicine, 42, p. 101218. doi:10.1016/j.eclinm.2021.101218.

IEEE

P. S. Kulkarni et al., “A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India,” EClinicalMedicine, vol. 42, p. 101218, 2021, doi: 10.1016/j.eclinm.2021.101218.

BibTeX

@article{kulkarni2021phase,
  title     = {{A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India}},
  author    = {Kulkarni, Prasad Suryakant and Padmapriyadarsini, Chandrasekaran and Vekemans, Johan and Bavdekar, Ashish and Gupta, Madhu and Kulkarni, Praveen and Garg, BS and Gogtay, Nithya and Tambe, Muralidhar and Lalwani, Sanjay and Singh, Kiranjit and Munshi, Renuka and Meshram, Sushant and Selvavinayagam, T. S. and Pandey, Krishna and Bhimarasetty, Devi Madhavi and Ramakrishnan, S. R. and Bhamare, Chetanraj and Dharmadhikari, Abhijeet and Vadakkedath, Rajeev and Bonhomme, Cyrille J. and Thakar, Madhuri Rajeev and Kurle, Swarali N. and Kelly, Elizabeth J. and Gautam, Manish and Gupta, Nivedita and Panda, Samiran and Bhargava, Balram and Shaligram, Umesh S. and Kapse, Dhananjay and others},
  journal   = {EClinicalMedicine},
  year      = {2021},
  volume    = {42},
  pages     = {101218},
  doi       = {10.1016/j.eclinm.2021.101218},
  url       = {https://doi.org/10.1016/j.eclinm.2021.101218}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202277
202399
20241414
202555
202622

Its field-weighted citation impact is 2.45: it has been cited 2.45 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research

  • COVID-19 vaccines
  • ChAdOx1 nCoV-19 vaccine
  • AZD1222
  • non-inferiority
  • immunogenicity
  • anti-spike IgG
  • vaccine safety
  • serious adverse events

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Kulkarni, P. S., Padmapriyadarsini, C., Vekemans, J., Bavdekar, A., Gupta, M., Kulkarni, P., Garg, B., Gogtay, N., Tambe, M., Lalwani, S., Singh, K., Munshi, R., Meshram, S., Selvavinayagam, T. S., Pandey, K., Bhimarasetty, D. M., Ramakrishnan, S. R., Bhamare, C., Dharmadhikari, A., . . . Gunale, B. (2021). A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India. EClinicalMedicine, 42, 101218. https://doi.org/10.1016/j.eclinm.2021.101218

How many times has this paper been cited?

37 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at EClinicalMedicine: sign in and open the PDF from this page.

Who wrote this paper?

Prasad Suryakant Kulkarni, Chandrasekaran Padmapriyadarsini, Johan Vekemans, Ashish Bavdekar, Madhu Gupta, Praveen Kulkarni, BS Garg, Nithya Gogtay, Muralidhar Tambe, Sanjay Lalwani, Kiranjit Singh, Renuka Munshi and 19 more.

What is the DOI of this paper?

10.1016/j.eclinm.2021.101218, permanently at https://doi.org/10.1016/j.eclinm.2021.101218. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.